Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetat...
Shilpa Medicare reported revenue of 12.86 billion INR for fiscal year 2025, up 11.7% from fiscal year 2024, and net income of 782.93 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 4.10 billion INR, up 28.3% from a year before. India was its largest region in fiscal year 2025, with 37% of revenue. Its market capitalization was 198.30 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.